Lee Chi-Hsin, Wu Chao-Jung, Yen Fang-Yi, Chiang Jia-Yun, Shen Ting-Jing, Leu Sy-Jye, Chang Chuang-Rung, Lo Hsiu-Jung, Tsai Bor-Yu, Mao Yan-Chiao, Andriani Valencia, Thenaka Priskila Cherisca, Wang Wei-Chu, Chao Yu-Pin, Yang Yi-Yuan
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, No. 301, Yuantong Rd., Zhonghe Dist., New Taipei City, 235, Taiwan.
Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University Inc., Taipei, 110301, Taiwan.
Appl Microbiol Biotechnol. 2025 Apr 8;109(1):85. doi: 10.1007/s00253-025-13469-3.
Candida albicans is a major opportunistic pathogen, responsible for nearly half of clinical candidemia cases. The rising prevalence of azole-resistant Candida species represents a significant clinical challenge, underscoring the urgent need for alternative therapeutic strategies. Monoclonal antibody-based therapies have emerged as a promising and cost-effective approach to combating Candida infections. Agglutinin-like sequence protein 3 (Als3), a key cell surface protein of C. albicans, plays a pivotal role in adherence and biofilm formation, both of which are essential for its pathogenesis. In this study, recombinant Als3 protein was purified and utilized to immunize chickens, resulting in the production of Als3-specific immunoglobulin Y (IgY) antibodies. Two single-chain variable fragment (scFv) antibody libraries were subsequently constructed using phage display technology, yielding transformant counts of 5.3 × 10 and 2.8 × 10, respectively. Phage-based enzyme-linked immunosorbent assay (ELISA) revealed enhanced signals following bio-panning, enabling the identification and sequence validation of three scFv antibodies. These scFv antibodies exhibited strong binding activities to Als3, as confirmed through ELISA and western blot analyses. Binding affinities were determined to be ~ 10⁻⁸ M via serial titration ELISA and competitive ELISA. Additionally, the selected scFv antibodies specifically recognized endogenous Als3 protein in C. albicans, as demonstrated by western blot and cell-based ELISA assays. In conclusion, this study successfully generated and characterized high-affinity scFv antibodies targeting Als3, which exhibited exceptional specificity and binding activity. These findings highlight their potential as promising immunotherapeutic candidates for the treatment of C. albicans infections. KEY POINTS: • The Als3 protein of C. albicans is a critical biomarker and therapeutic target • Chicken-derived scFv antibodies against Als3 were developed via phage display • The scFv antibodies showed strong binding to endogenous Als3 in C. albicans.
白色念珠菌是一种主要的机会性病原体,导致近一半的临床念珠菌血症病例。耐唑类念珠菌物种的患病率不断上升,这是一个重大的临床挑战,凸显了对替代治疗策略的迫切需求。基于单克隆抗体的疗法已成为对抗念珠菌感染的一种有前景且具有成本效益的方法。凝集素样序列蛋白3(Als3)是白色念珠菌的一种关键细胞表面蛋白,在黏附和生物膜形成中起关键作用,而这两者对其发病机制都至关重要。在本研究中,重组Als3蛋白被纯化并用于免疫鸡,从而产生了Als3特异性免疫球蛋白Y(IgY)抗体。随后利用噬菌体展示技术构建了两个单链可变片段(scFv)抗体文库,转化子计数分别为5.3×10和2.8×10。基于噬菌体的酶联免疫吸附测定(ELISA)显示,生物淘选后信号增强,从而能够鉴定和序列验证三种scFv抗体。通过ELISA和蛋白质印迹分析证实,这些scFv抗体对Als3具有强结合活性。通过连续滴定ELISA和竞争性ELISA测定,结合亲和力约为10⁻⁸M。此外,如蛋白质印迹和基于细胞的ELISA分析所示,所选的scFv抗体能特异性识别白色念珠菌中的内源性Als3蛋白。总之,本研究成功产生并表征了靶向Als3的高亲和力scFv抗体,这些抗体表现出卓越的特异性和结合活性。这些发现突出了它们作为治疗白色念珠菌感染的有前景的免疫治疗候选物的潜力。关键点:•白色念珠菌的Als3蛋白是一种关键的生物标志物和治疗靶点•通过噬菌体展示开发了针对Als3的鸡源scFv抗体•scFv抗体对白色念珠菌中的内源性Als3显示出强结合。